IP Library Granted Patent US 10,501,777
Granted Patent B2
US 10,501,777 · App. 15/211,236 · Granted Dec 10, 2019

Simultaneous quantification of a plurality of proteins in a user-defined region of a cross-sectioned tissue

Inventors: Joseph M. Beechem (Eugene, OR); Gordon Mills (Houston, TX); Charles Warren (Bremerton, WA); Chris Merritt (Seattle, WA); Jaemyeong Jung (Bellevue, WA); Dwayne L. Dunaway (Seattle, WA); Scott Crowder (Seattle, WA)
Assignees: NanoString Technologies, Inc.; Board of Regents, The University of Texas System
C12Q1/6832C12Q1/6841
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,501,777
App. No.
15/211,236
Filed
Jul 15, 2016
Granted
Dec 10, 2019
Kind
B2
Art Unit
1636
USPC
435/69.1
Abstract

The present invention relates to, among other things, probes, compositions, methods, and kits for simultaneous, multiplexed detection and quantification of protein expression in a user-defined region of a tissue, user-defined cell, and/or user-defined subcellular structure within a cell.

Claims (48)

1. A method of producing a spatially-resolved profile of protein abundance in a tissue sample comprising:

a) contacting the tissue sample with a solution comprising at least 15 species of probes, the probes comprising a target-binding domain, a signal oligonucleotide, and a photo-cleavable motif located between the target-binding domain and the signal oligonucleotide,

wherein each species of probe comprises a unique protein target-binding domain that hybridizes to one of the at least 15 target proteins and a unique signal oligonucleotide specific for the target protein;

b) illuminating a first location of the tissue sample with light sufficient to release signal oligonucleotides at the first location;

c) collecting the signal oligonucleotides released in step (b) from the solution proximal to the first location;

d) identifying and quantifying via multiplexed immunohistochemistry the signal oligonucleotides collected in step (c), thereby determining the abundance of the at least 15 target proteins in the first location;

e) illuminating at least a second location of the tissue sample with light sufficient to release the signal oligonucleotides at the at least second location;

f) collecting the signal oligonucleotides released in step (e) from the solution proximal to the at least second location;

g) identifying and quantifying via multiplexed immunohistochemistry the signal oligonucleotides collected in step (f), thereby determining the abundance of the at least 15 target proteins in the at least second location; and

h) comparing the abundance of the at least 15 target proteins in the first location of the tissue sample to the abundance of the at least 15 target proteins in the at least second location of the tissue sample, thereby generating a spatially-resolved profile of protein abundance in the tissue sample.

2. The method of claim 1 , wherein the first location and the at least second location each comprise at least one cell.

3. The method of claim 2 , wherein the at least one cell in the first location and the at least one cell in the at least second location are the same cell type.

4. The method of claim 2 , wherein the at least one cell in the first location and the at least one cell in the at least second location are distinct cell types.

5. The method of claim 4 , wherein the at least one cell in the first location is an abnormal cell and the at least one cell in the at least second location is a normal cell.

6. The method of claim 1 , wherein the tissue sample is directly immobilized to a surface or is indirectly immobilized to the surface.

7. The method of claim 1 , wherein the tissue sample is a 2 to 1000 μm thick tissue section.

8. The method of claim 7 , wherein the tissue section is obtained from a formalin-fixed paraffin embedded (FFPE) sample.

9. The method of claim 1 , wherein the tissue sample comprises at least one cell, wherein the at least one cell is a cultured cell, a primary cell, or a dissociated cell from an explant.

10. The method of claim 1 , wherein the tissue sample is fixed or unfixed.

11. The method of claim 1 , further comprising staining or labeling the tissue to allow visualization of a subcellular, cellular, or tissue-related structure.

12. The method of claim 1 , wherein the signal oligonucleotide is a single-stranded nucleic acid or a partially double-stranded nucleic acid.

13. The method of claim 1 , further comprising a purification step to remove intact probe molecules from the released signal oligonucleotides, the purification step comprising an affinity purification comprising contacting an intact probe with an immobilized oligonucleotide that is complementary to a portion of the intact probe or an immobilized antibody or protein-binding motif that recognizes and binds to a portion of the intact probe.

14. The method of claim 13 , wherein the target binding domain of the intact probe comprises a universal purification tag or sequence that is partially complementary to the immobilized oligonucleotide or is capable of being recognized or bound by the immobilized antibody or protein-binding motif.

15. The method of claim 1 , wherein the source of light is selected from the group consisting of an arc-lamp, a laser, a focused UV light source, and light emitting diode (LED).

16. The method of claim 1 , wherein the light is UV light.

17. The method of claim 1 , wherein illuminating a first location of the tissue sample comprises irradiating at least one subcellular structure present in the first location.

18. The method of claim 1 , wherein illuminating a second location of the tissue sample comprises irradiating at least one subcellular structure present in the at least second location.

19. The method of claim 17 , wherein identifying the signal oligonucleotides released in the first location of the tissue sample comprises determining the abundance of the at least 15target proteins in the at least one irradiated subcellular structure.

20. The method of claim 18 , wherein identifying the signal oligonucleotides released in the at least second location of the tissue sample comprises determining the abundance of the at least 15 target proteins in the at least one irradiated subcellular structure.

21. The method of claim 1 , wherein the target-binding domain is selected from the group consisting of an antibody, a peptide, an aptamer, and a peptoid.

22. The method of claim 1 , wherein the solution proximal to the first location is directly above the first location.

23. The method of claim 1 , wherein the solution proximal to the at least second location is directly above the at least second location.

24. The method of claim 1 , wherein the proximal solution is collected by aspirating.

25. The method of claim 1 , wherein the solution proximal to the first location and the solution proximal to the at least second location are collected using a pipette, a capillary tube, a microarray pin or a micro-aspirator.

26. The method of claim 25 , wherein the capillary tube comprises an optical device capable of transmitting light to the at least one cell.

27. The method of claim 25 , wherein the pipette or microarray pin is attached to an array comprising a plurality of pipettes or microarray pins.

28. The method of claim 1 , wherein the proximal solution comprises an anionic polymer or salmon sperm DNA or the collected signal oligonucleotide is added to a solution comprising an anionic polymer or salmon sperm DNA.

29. The method of claim 28 , wherein the anionic polymer is dextran sulfate.

30. The method of claim 1 , wherein first location and the at least second location are illuminated using a laser scanning device or a digital mirror device (DMD).

31. The method of claim 1 , wherein the spatially-resolved profile exhibits a linear dynamic range of >5 logs.

32. The method of claim 1 , wherein the tissue sample is attached to a slide and is first imaged using fluorescence.

33. The method of claim 1 , wherein the probes are provided at a concentration of 5 nM or less.

34. The method of claim 1 , wherein steps (b) and (e) are performed simultaneously.

35. The method of claim 1 , wherein steps (b) and (e) are performed sequentially.

36. The method of claim 1 , wherein steps (c) and (f) are performed simultaneously.

37. The method of claim 1 , wherein steps (c) and (f) are performed sequentially.

38. The method of claim 1 , wherein steps (d) and (g) are preformed simultaneously.

39. The method of claim 1 , wherein steps (d) and (g) are preformed sequentially.

Assignments (10)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 7, 2024
From: NANOSTRING TECHNOLOGIES, INC.
To: BRUKER SPATIAL BIOLOGY, INC.
Reel/Frame 067664/0241 →
RELEASE OF SECURITY INTEREST Recorded May 16, 2024
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: NANOSTRING TECHNOLOGIES, INC.
Reel/Frame 067453/0577 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 16, 2024
From: NANOSTRING TECHNOLOGIES, INC.
To: BRUKER SPATIAL BIOLOGY, INC.
Reel/Frame 067932/0109 →
RELEASE OF SECURITY INTEREST Recorded May 16, 2024
From: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION
To: NANOSTRING TECHNOLOGIES, INC.
Reel/Frame 067453/0565 →
SECURITY INTEREST Recorded Feb 8, 2024
From: NANOSTRING TECHNOLOGIES, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 066528/0634 →
SECURITY INTEREST Recorded Nov 7, 2023
From: NANOSTRING TECHNOLOGIES, INC.
To: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION
Reel/Frame 065490/0058 →
TERMINATION AND RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Mar 10, 2020
From: CRG SERVICING LLC
To: NANOSTRING TECHNOLOGIES, INC.
Reel/Frame 052136/0021 →
SECURITY INTEREST Recorded Oct 16, 2018
From: NANOSTRING TECHNOLOGIES, INC.
To: CRG SERVICING LLC
Reel/Frame 047240/0439 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 2, 2016
From: BEECHEM, JOSEPH M.; WARREN, CHARLES; MERRITT, CHRIS; JUNG, JAEMYEONG; DUNAWAY, DWAYNE L.; CROWDER, SCOTT
To: NANOSTRING TECHNOLOGIES, INC.
Reel/Frame 039621/0194 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 29, 2016
From: MILLS, GORDON B.
To: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 039287/0191 →
Continuity (5)
Provisional Application 62193819 · Jul 17, 2015
Provisional Application 62261654 · Dec 1, 2015
Provisional Application 62277283 · Jan 11, 2016
Provisional Application 62323018 · Apr 15, 2016
Related Publication 20170016909A1 · Jan 19, 2017
Cited By (67)
US 12,188,085 US 12,188,087 US 12,195,790 US 12,203,134 US 12,203,136 US 12,209,273 US 12,209,280 US 12,215,379 US 12,227,796 US 12,234,507 US 12,241,060 US 12,241,890 US 12,258,624 US 12,264,358 US 12,270,071 US 12,270,074 US 12,270,077 US 12,275,984 US 12,275,988 US 12,281,357 US 12,286,673 US 12,297,486 US 12,297,499 US 12,319,956 US 12,325,877 US 12,331,347 US 12,344,892 US 12,360,105 US 12,365,935 US 12,365,942 US 12,365,944 US 12,371,688 US 12,378,607 US 12,391,984 US 12,399,123 US 12,400,733 US 12,404,544 US 12,405,264 US 12,435,361 US 12,435,364 US 12,442,045 US 12,460,251 US 12,460,319 US 12,467,086 US 12,497,653 US 12,509,717 US 12,516,369 US 12,529,094 US 12,529,096 US 12,553,079 US 12,559,790 US 12,559,791 US 12,565,671 US 12,566,113 US 12,571,029 US 12,618,099 US 12,624,475 US 12,630,869 US 12,662,699 US 12,668,835 US 12,674,196 US 12,687,494 US 12,692,484 US 12,703,879 US 12,709,771 US 12,716,092 US 12,718,518